Beactica Therapeutics to present breakthrough in YAP–TEAD programme at the Hippo Pathway Drug Development Summit 2023
Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its YAP–TEAD programme has been selected for an oral presentation at the 2[nd] Hippo Pathway Targeted Drug Development Summit 2023. The conference will take place on May 23–35, 2023, in Boston, Massachusetts.Dr Peter Brandt, Head of Chemistry, will present a talk entitled Specific Degraders of TEADs Based on Interface 3 Binding on Thursday May 25, 2023, at 2:00 – 2:30 PM in the Boston Park Plaza. The presentation will showcase a breakthrough in the development of novel cell-active targeted degraders of